APA (7th ed.) Citation

Wakelee, H., Gettinger, S., Engelman, J., Jänne, P., West, H., Subramaniam, D., . . . Lara, P. N. J. (2017). A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer. Cancer Chemotherapy & Pharmacology, 79(5), 923. https://doi.org/10.1007/s00280-017-3283-z

Chicago Style (17th ed.) Citation

Wakelee, Heather, et al. "A Phase Ib/II Study of Cabozantinib (XL184) with or Without Erlotinib in Patients with Non-small Cell Lung Cancer." Cancer Chemotherapy & Pharmacology 79, no. 5 (2017): 923. https://doi.org/10.1007/s00280-017-3283-z.

MLA (9th ed.) Citation

Wakelee, Heather, et al. "A Phase Ib/II Study of Cabozantinib (XL184) with or Without Erlotinib in Patients with Non-small Cell Lung Cancer." Cancer Chemotherapy & Pharmacology, vol. 79, no. 5, 2017, p. 923, https://doi.org/10.1007/s00280-017-3283-z.